A5042323208- Lung Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Medical research and treatments
- Health and Medical Education
- Education and Digital Technologies
- Connective tissue disorders research
- Multiple and Secondary Primary Cancers
- Cancer Immunotherapy and Biomarkers
- Cancer Diagnosis and Treatment
Universidad Autónoma de Bucaramanga
2024
Hospital Garcia de Orta
2008-2019
The main aim of the study was to evaluate efficacy and safety profile Nivolumab, an immune-checkpoint-inhibitor antibody, in advanced, previously treated, Non-Small Cell Lung Cancer (NSCLC) patients, a real world setting. We performed retrospective, multicentre data analysis patients who were included Portuguese Nivolumab Expanded Access Program (EAP). Eligibility criteria histologically or citologically confirmed NSCLC, stage IIIB IV, evaluable disease, sufficient organ function at least...
Until 2004, docetaxel in monotherapy was the standard for second-line treatment of non-small cell lung cancer (NSCLC). Pemetrexed (P) has shown similar activity this setting with a better adverse event profile. In Portugal, it introduced October 2004. We have carried out retrospective analysis patients (pts) who received P NSCLC Portugal from 2004 to December 2006. Data were collected records pts locally advanced or metastatic and failed first-line chemotherapy enrolled centers participating...